Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(8):510-512; doi:10.1093/jnci/djj173
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bankhead, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bankhead, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Intraperitoneal Therapy for Advanced Ovarian Cancer: Will It Become Standard Care?

Charles Bankhead

The first 10% of the full text of this article appears below.

The National Cancer Institute's recent endorsement of intraperitoneal (IP) chemotherapy as the preferred method of treating advanced ovarian cancer has met with cautious optimism about the technique's chances of helping more women survive longer.

Results of a Gynecologic Oncology Group (GOG) study, which prompted the NCI announcement in January, demonstrated that IP chemotherapy improves survival in patients with surgically treated ovarian cancer when added to intravenous (IV) therapy, compared with IV therapy alone. However, the study did nothing to assuage concerns about IP therapy's toxicity and tolerability, as fewer than half of patients completed the planned treatment. The tradeoff between survival and tolerability sets the stage for future clinical investigation to identify effective IP regimens that are more patient friendly.

"[IP chemotherapy] is not a magic bullet," said Deborah Armstrong, M.D., associate professor of medical oncology at Johns Hopkins University . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?